Leva Clinic, chronic pain and medical cannabis leaders, raise $3.5m to transform treatment for UK pain patients
Ryan Allway
November 8th, 2022
News, Top News
Leva Clinic has secured $3.5m USD (£3m GBP) of funding from Óskare Capital and Justin Hartfield to accelerate innovation in medical cannabis therapeutics and scale the delivery of digital solutions for chronic pain patients.
Leva Clinic has announced that it has secured $3.5m USD (£3m GBP) of funding from Óskare Capital and Justin Hartfield to accelerate innovation in medical cannabis therapeutics and scale the delivery of digital solutions for chronic pain patients.
- Leva Clinic (“Leva”) operates the UK’s first online clinic for chronic pain, owns one of the UK’s leading brands of medical cannabis (Satoline), and is a founding member of the largest observational medical cannabis study in the UK (Project Twenty21)
- Justin Hartfield, founder of Weedmaps, one of the world’s largest integrated cannabis technology platforms, has led a $3.5m USD (£3m GBP) investment in Leva alongside Óskare Capital, a European medical and pharmaceutical cannabis fund.
- Funding will grow the clinic’s reach, strengthen and broaden partnerships with the NHS and other healthcare providers, and improve ongoing patient experience with a mobile app.
One quarter of adults in the UK are living with a pain condition that has lasted over three months, with chronic pain having been dubbed a “silent epidemic”. Pain costs the UK economy significantly more than cancer and heart disease, almost as much as diabetes and obesity costs. A lack of personalised treatment options and difficulties in accessing clinical support currently prevents millions of adults from living a life without pain, and fueling a surge in opioid-related deaths.
Established in 2019, Leva Clinic is the UK’s first online clinic for people living with chronic pain. Regulated by the Care Quality Commission. Leva’s services are accessible through the Boots Health Hub, and the clinic also has live partnerships with several NHS trusts to deliver digital therapeutic services and consultant-led patient care plans.
Justin Hartfield, who founded global cannabis technology platform Weedmaps in 2008, makes the investment via his private investment office 2420 Partners. The investment is the first for 2420 in the UK and the second in Europe. He said:
“Our investment in Leva is perfectly aligned with our goal to support emerging businesses in the pain management space globally. Leva is on the path to being a market leader in delivering innovative pain management solutions by industry-leading pain experts in the UK. We are excited to partner with the company in its next chapter of growth.”
Leva is a founding member of Project Twenty21, the largest observational medical cannabis study in the UK. Leva’s Satoline range of medical cannabis-based medicines is part of the formulary for the trial, gathering evidence on the efficacy of medical cannabis-based medicines.
Leva is also one of three suppliers participating in the ‘I Am Billy’ Foundation RESCAS program (Refractory Epilepsy Specialist Clinical Advisory Service), set up in 2020 following a legal challenge brought by campaigner Charlotte Caldwell against the UK government. It provides a much-needed route to NHS-funded medical cannabis for people under the age of 18 affected by refractory epilepsy.
Leva co-founder and CEO Eric Bystrom said:
“Leva’s unique patient centric platform is delivering for our patients, and with this investment we intend to further increase our reach across the UK and continue to build our offering through digital access. Justin’s experience in developing digital offerings coupled with Oskare’s life sciences expertise make them the perfect partners for this next stage of our journey.”
Óskare Capital is a European medical and pharmaceutical cannabis fund, unlocking the endocannabinoid system through Life Sciences and Deep Tech.
Dr John Rogers, Neurologist and co-founder of Óskare, on joining Leva’s board said:
We have been impressed by Leva’s approach to patient care, also affirmed by their NHS contracts and recent CQC report. Leva has assembled a highly experienced team of pain management experts, and we are excited to help Leva make these patient services available across the UK.”
Oliver Lamb, Co-Founder and Investment Manager at Óskare Capital, said:
“We are excited about our investment in Leva and their much needed pain management platform. One of the key issues that Óskare Capital seeks to address in the medical cannabis market is patient access, and Leva are breaking down the barriers for those patients most in need. Having been in discussions with the Leva team for over a year, we have been continually impressed by their vision and dedication.”
Dr Arun Bhaskar, Consultant in Pain Medicine and President of the British Pain Society, will also join the board as an independent director. He adds:
“The dedication of the team to both best clinical practice and patient care is resulting in excellent patient outcomes”
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
The Gluu is the first ever distribution platform serving the larger cannabis industry, linking together suppliers, manufacturers, reps, retailers and customers. If you sell products think of us as the B2B Amazon of the industry.
Mindleap is developing an advanced digital health platform that will provide support for people that are looking to achieve personal transformations and overcome mental health challenges.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
